Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk and identify a subgroup of patients sensitive to sulfonylureas.

MLA

Meulebrouck, Sarah, et al. “Pathogenic Monoallelic Variants in GLIS3 Increase Type 2 Diabetes Risk and Identify a Subgroup of Patients Sensitive to Sulfonylureas.” Diabetologia, vol. 67, no. 2, Feb. 2024, pp. 327–32. EBSCOhost, https://doi.org/10.1007/s00125-023-06035-x.

APA

Meulebrouck, S., Scherrer, V., Boutry, R., Toussaint, B., Vaillant, E., Dechaume, A., Loiselle, H., Balkau, B., Charpentier, G., Franc, S., Marre, M., Baron, M., Vaxillaire, M., Derhourhi, M., Boissel, M., Froguel, P., & Bonnefond, A. (2024). Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk and identify a subgroup of patients sensitive to sulfonylureas. Diabetologia, 67(2), 327–332. https://doi.org/10.1007/s00125-023-06035-x

Chicago

Meulebrouck, Sarah, Victoria Scherrer, Raphaël Boutry, Bénédicte Toussaint, Emmanuel Vaillant, Aurélie Dechaume, Hélène Loiselle, et al. 2024. “Pathogenic Monoallelic Variants in GLIS3 Increase Type 2 Diabetes Risk and Identify a Subgroup of Patients Sensitive to Sulfonylureas.” Diabetologia 67 (2): 327–32. doi:10.1007/s00125-023-06035-x.